Federal Register Notice: FDA’s Endocrinologic and Metabolic Drugs Advisory Committee will meet 7/9 from 8:30 a.m. to 5 p.m. at the Holiday Inn, Bethesda, MD. The committee will discuss a new drug application, Crestor (rosuvastatin calcium) tablets, AstraZeneca Pharmaceuticals (agent for iPR Pharmaceuticals, Inc.), for the proposed indication of treatment of hypercholesterolemia and mixed dyslipidemia. To view this notice, click here.
